Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Clinical Study on the Immune Response Characteristics of Novel Coronavirus and Influenza Virus Infection

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This is an open-label, prospective observational study in people 18 years of age and older designed to track changes in the dynamics of the respiratory and peripheral blood immune response in people infected with influenza virus and new coronaviruses, and to resolve the characteristics of the virus-induced natural immune response.

Who May Be Eligible (Plain English)

Who May Qualify: 1. volunteers aged 18 years and above at the time of screening; 2. willing to sign a consent form obtained from volunteers and volunteers/witnesses able to sign the willing to sign a consent form form; 3. an interval of ≥3 months from the last COVID-19 or influenza vaccination; 4. an interval of ≥ 3 months from the last respiratory viral infection such as COVID-19 or Influenza virus occurs; 5.1 cohort 1:novel coronavirus virus antigen-positive and within 48 hours of onset of symptoms of infection; 5.2 cohort 2:influenza virus antigen-positive and within 48 hours of onset of symptoms of infection; 5.3 cohort 3:novel coronavirus and influenza virus antigen-negative, no febrile symptoms, and no symptoms of viral or bacterial respiratory infections. Who Should NOT Join This Trial: 1. known or suspected concomitant more serious and medically unstable disease in the judgment of the investigator, including: respiratory disease, tuberculosis, acute infections or active chronic disease, hepatic or renal disease, cardiovascular disease (cardiorespiratory failure), hypertension (systolic blood pressure ≥160 mmHg, diastolic blood pressure ≥100 mmHg), malignant tumors, infectious or allergic skin diseases, and the presence of HIV infection; 2. Absence of spleen or functional absence of spleen; 3. immunosuppressive therapy, anti-allergy therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and superficial corticosteroid therapy for acute uncomplicated dermatitis) within the past 6 months; 4. Received blood products within the past 3 months; 5. has received other vaccines or investigational drugs within the past 1 month; 6. is receiving anti-tuberculosis treatment; 7. In the judgment of the investigator, due to a variety of medical, psychological, social, or other conditions that are contrary to the trial protocol or that affect the signing of willing to sign a consent form by the volunteer. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: 1. volunteers aged 18 years and above at the time of screening; 2. informed consent obtained from volunteers and volunteers/witnesses able to sign the informed consent form; 3. an interval of ≥3 months from the last COVID-19 or influenza vaccination; 4. an interval of ≥ 3 months from the last respiratory viral infection such as COVID-19 or Influenza virus occurs; 5.1 cohort 1:novel coronavirus virus antigen-positive and within 48 hours of onset of symptoms of infection; 5.2 cohort 2:influenza virus antigen-positive and within 48 hours of onset of symptoms of infection; 5.3 cohort 3:novel coronavirus and influenza virus antigen-negative, no febrile symptoms, and no symptoms of viral or bacterial respiratory infections. Exclusion Criteria: 1. known or suspected concomitant more serious and medically unstable disease in the judgment of the investigator, including: respiratory disease, tuberculosis, acute infections or active chronic disease, hepatic or renal disease, cardiovascular disease (cardiorespiratory failure), hypertension (systolic blood pressure ≥160 mmHg, diastolic blood pressure ≥100 mmHg), malignant tumors, infectious or allergic skin diseases, and the presence of HIV infection; 2. Absence of spleen or functional absence of spleen; 3. immunosuppressive therapy, anti-allergy therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and superficial corticosteroid therapy for acute uncomplicated dermatitis) within the past 6 months; 4. Received blood products within the past 3 months; 5. has received other vaccines or investigational drugs within the past 1 month; 6. is receiving anti-tuberculosis treatment; 7. In the judgment of the investigator, due to a variety of medical, psychological, social, or other conditions that are contrary to the trial protocol or that affect the signing of informed consent by the volunteer.

Treatments Being Tested

OTHER

Nasal swab/Nasopharyngeal swab/Blood sample collection

Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing

OTHER

Nasal swab/Nasopharyngeal swab/Blood draw

Visit 1/2/3:Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing

OTHER

Nasal swab/Nasopharyngeal swab/Blood draw

Visit 1/2/3:Collect nasal or nasopharyngeal swab samples, 15ml anticoagulant samples and 3ml procoagulant samples, as well as 2ml blood samples for blood routine testing and C-reactive protein testing

Locations (2)

Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China